
Neurocrine Biosciences, Inc.: updates and filings
Price
$156.59
November 19, 2026Market cap $15.7B
What Ploutos Investor adds for Neurocrine Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 1, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
July 2026
May 2026
- 28ThuPeopleOfficer or director change, shareholder voteDocument
- 18MonDealMaterial agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosureDocument
- 5TueReportQuarterly report · for the period to Mar 31, 2026Document
- 5TueResultsResults of operationsDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 2, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operationsForm8-K
- Oct 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 28, 2026Officer or director changeForm8-K
- Jul 31, 2026Shares registered for employeesFormS-8
- Jul 31, 2026Financial statements and exhibits (amendment)Form8-K/A
- Jul 31, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operationsForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 28, 2026Officer or director change, shareholder voteForm8-K
- May 18, 2026Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosureForm8-K
- May 18, 2026Filing (amendment)FormSC TO-T/A
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Filing (amendment)FormSC TO-T/A
- Apr 28, 2026Filing (amendment)FormSC TO-T/A
- Apr 20, 2026FilingFormSC TO-T
- Apr 15, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 15, 2026Additional annual meeting materialFormDEFA14A
- Apr 15, 2026Annual meeting proxy statementFormDEF 14A
- Apr 7, 2026FilingFormSC TO-C
- Apr 6, 2026FilingFormSC TO-C
- Apr 6, 2026FilingFormSC TO-C
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 2, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations | Document |
| Oct 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 28, 2026 | 8-K | Officer or director change | Document |
| Jul 31, 2026 | S-8 | Shares registered for employees | Document |
| Jul 31, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Jul 31, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 28, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 18, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosure | Document |
| May 18, 2026 | SC TO-T/A | Filing (amendment) | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SC TO-T/A | Filing (amendment) | Document |
| Apr 28, 2026 | SC TO-T/A | Filing (amendment) | Document |
| Apr 20, 2026 | SC TO-T | Filing | Document |
| Apr 15, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 15, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 15, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 7, 2026 | SC TO-C | Filing | Document |
| Apr 6, 2026 | SC TO-C | Filing | Document |
| Apr 6, 2026 | SC TO-C | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 10, 1996.
The full analysis
What do Neurocrine Biosciences's filings show?
The filings are where every one of Neurocrine Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.